Zydus Wellness reports net profit of 5.1 crore rupees with revenue growth to 1,126 crore rupees in the second quarter

Zydus Lifesciences reported a 26.6% decline in consolidated net profit for the September quarter, reaching 925.5 crore rupees, which was attributed to increased expenses. In the corresponding period last fiscal year, the company reported a net profit of 1,260.9 crore rupees, according to regulatory filings submitted to the stock exchanges.

For the reporting quarter, operating revenue increased to 7,909.6 crore rupees compared to 6,123.2 crore rupees a year earlier. However, Zydus's total expenses rose significantly, amounting to 6,806.6 crore rupees in the current quarter, whereas they were 4,509 crore rupees in the same period last year.

During this quarter, the pharmaceutical business accounted for 83% of the company's sales. Notably, the prescription drug division in India generated revenue of 1,884.4 crore rupees, showing an 18% year-on-year growth. The North American prescription drug business generated revenue of 3,314.5 crore rupees, demonstrating a 21% growth, resulting from sustained expansion of the core business volume and the ongoing scaling of the American specialty segment.

Zydus Lifesciences Managing Director, Sharvil Patel, noted that the second-quarter results reflect a strong overall momentum led by branded segments in India, international markets, and the wellness sector. He emphasized that the share of branded product sales in the US grew to 16%, indicating the company's systematic shift towards a more differentiated portfolio focused on specialized products. Patel added that the company expects approval and launch of Saroglitazar in the US, which is the first domestic discovery of a new chemical entity (NCE) and marks a significant milestone in its development.

Furthermore, for the period from April to September of the 2027 fiscal year, the pharmaceutical company's net profit decreased by 30.86% to 1,885.9 crore rupees compared to 2,727.7 crore rupees a year earlier. At the time of publication, Zydus Lifesciences shares were trading at BSE at Rs 1,197.50 per share, down by 3.35%.

Kolte-Patil Developers Ltd, which has support from Blackstone and is based in Pune, reported consolidated net profit of ₹5.70 crore for the quarter ending in September.

In the previous year, the company incurred a net loss of ₹11.14 crore. According to regulatory filings, total revenue in the second quarter of the current fiscal year exceeded double, reaching ₹351.51 crore compared to ₹161.75 crore in the same period last year.

For the period from April to September 2026-27, net profit was ₹152.36 crore, whereas last year recorded a net loss of ₹28.02 crore. Furthermore, total revenue for the first half of the current fiscal year increased to ₹1,288.13 crore compared to ₹258.56 crore in the corresponding period of the previous year.

Listen to this article

Hrishikesh Parandekar, the company's CEO, noted that the first six months of the current fiscal year were a landmark period marked by record business performance and significant portfolio expansion. He reported achieving record pre-sales both quarterly and semi-annually, which grew by 52% and 27% year-on-year, respectively, as well as the highest ever semi-annual total revenue for the company, reflecting stable execution across the entire project portfolio.

The CEO emphasized that the company added six redevelopment projects to its Mumbai portfolio, with a potential aggregate revenue of ₹6,000 crore. He also stated that thanks to a robust launch plan, good project completion visibility, and sustained sales demand, the company is well-positioned to maintain the first-half results and ensure a strong finish to the fiscal year '27 in terms of operational and financial parameters.

Founded in 1991, Kolte-Patil Developers is one of India's leading developers, with presences in Mumbai, Pune, and Bangalore. In fiscal year '26, Blackstone acquired a 40% stake in the company. The company has developed and built over 82 projects, including residential complexes, integrated townships, commercial complexes, and IT parks, with a total saleable area exceeding 34 million square feet.

Automotive market leader, Maruti Suzuki India Ltd, reported on Tuesday a 26.36% decline in its consolidated net profit for the second quarter ending in September. The profit amounted to 2,466.1 crore rupees. This decrease occurred despite revenue growth, which was driven by record car sales volumes during the quarter; however, it was caused by increased raw material costs linked to the Middle East conflict.

According to regulatory filings, the company recorded a net profit of 3,349 crore rupees in the same quarter of the previous fiscal year. For the period from July to September, total operating revenue increased to 53,355.5 crore rupees compared to 42,344.2 crore rupees in the same period of the 2025-26 fiscal year, as stated in the company's reports.

Total expenses for July-September also rose to 50,619 crore rupees compared to 39,018.4 crore rupees a year earlier. Furthermore, the cost of materials consumed in the second quarter grew to 37,488.5 crore rupees from 25,324.2 crore rupees in the corresponding period of the last fiscal year.

Financial Performance Details

In its statement, Maruti Suzuki India specified that the operating profit (EBIT) for this quarter reached 2,803.7 crore rupees, whereas it was 3,382 crore rupees in Q2 FY25-26. This reduction is attributed to rising raw material prices due to the Middle East conflict. Nevertheless, compared to Q1 FY26-27, there was a consistent growth of 10.8%. However, non-operating income sharply decreased in the second quarter due to losses from investment surplus valuation.

The company announced achieving an all-time high quarterly sales volume of 696,654 units, representing a 26.5% increase compared to the same period last year. The company's growth in the domestic passenger vehicle market was extensive: small car sales increased by 35.9%, and SUV sales increased by 68.2%. Newly launched company SUVs received a strong market response, contributing to such sustained growth.

Maruti Suzuki India reported that its domestic market share increased by 2.2 percentage points, reaching 40.8%. The company noted that the recent increase in production capacity allowed it to meet high demand. Despite the expansion of production capabilities, demand continued to outstrip supply, leading to a low network inventory of about 17 days and pending bookings of approximately 200,000 units by the end of the quarter.

In export markets, despite the complex geopolitical situation, the company managed to ship 108,119 units in Q2 FY 2026-27, compared to 110,487 units in Q2 FY25-26.